Trial
NCT01235793
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Cedars-Sinai Medical Center
Collaborators
—
Condition
B-Cell Lymphoma Originating in the CNS
Intervention
Temozolomide
Why stopped
The clinical trial was terminated due to poor enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-20